View Article

Abstract

Many patients with advanced type 2 diabetes mellitus (T2DM) and all patients with T1DM require insulin to keep blood glucose levels in the target range. The most common route of insulin administration is subcutaneous insulin injections. There are many ways to deliver insulin subcutaneously such as vials and syringes, insulin pens, and insulin pumps. Though subcutaneous insulin delivery is the standard route of insulin administration, it is associated with injection pain, needle phobia, lipodystrophy, noncompliance and peripheral hyperinsulinemia. Therefore, the need exists for delivering insulin in a minimally invasive or noninvasive and in most physiological way. Inhaled insulin was the first approved noninvasive and alternative way to deliver insulin, but it has been withdrawn from the market. Technologies are being explored to make the noninvasive delivery of insulin possible. Some of the routes of insulin administration that are under investigation are oral, buccal, nasal, peritoneal and transdermal. This review article focuses on the past, present and future of various insulin delivery techniques. This article has focused on different possible routes of insulin administration with its advantages and limitation and possible scope for the new drug development.

Keywords

Diabetes mellitus, inhaled insulin, insulin delivery, oral insulin, technology, closed-loop system, artificial pancreas

Reference

  1. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013. [Last accessed on 2013 Sep 16]. The Global Burden. International Diabetes Federation. Available from: http://www.idf.org/diabetesatlas/5e/theglobal-burden . [Google Scholar]
  2. Garg SK, Michels AW, Shah VN. Use of non-insulin therapies for type 1 diabetes. Diabetes Technol Ther. 2013;15:901–8. [PubMed] [Google Scholar]
  3. U.K. prospective diabetes study 16. Overview of 6 yers’ therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249–58. [PubMed] [Google Scholar]
  4. Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013;15:727–32. [PubMed] [Google Scholar]
  5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86. [PubMed] [Google Scholar]
  6. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90:450–9. [PubMed] [Google Scholar]
  7. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab. 2013;98:1845–59. [PubMed] [Google Scholar]
  8. The history of injecting and the development of the syringe. Exchange supply tools for harm reduction. [Last accessed on 2013 Sep 16]. Available from: http://www.exchangesupplies.org/article_history_of_injecting_and_development_of_the_syringe.php .
  9. Milestones BD. [Last accessed on 2013 Sep 16]. Available from: http://www.bd.com/aboutbd/history/
  10. Fry A. Insulin delivery device technology 2012: Where are we after 90 years? J Diabetes Sci Technol. 2012;6:947–53. [PMC free article] [PubMed] [Google Scholar]
  11. Burdick P, Cooper S, Horner B, Cobry E, McFann K, Chase HP. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes. 2009;10:116–9. [PubMed] [Google Scholar]
  12. Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4:505–13. [PMC free article] [PubMed] [Google Scholar]
  13. Novo Nordisk Blue sheet. Quarterly perspective on diabetes and chronic diseases. 2010. [Last accessed on 2014 Sep 13]. Available from: http://www.press.novonordisk-us.com/bluesheet-issue2/downloads/NovoNordisk_Bluesheet_Newsletter.pdf .
  14. Penfornis A, Personeni E, Borot S. Evolution of devices in diabetes management. Diabetes Technol Ther. 2011;13(Suppl 1):S93–102. [PubMed] [Google Scholar]
  15. Ignaut DA, Venekamp WJ. HumaPen Memoir: A novel insulin-injecting pen with a dose-memory feature. Expert Rev Med Devices. 2007;4:793–802. [PubMed] [Google Scholar]
  16. Reynholds C, Antal Z. Analysis of the NovoPen Echo for the delivery of insulin: A comparison of usability, functionality and preference among pediatric subjects and their parents, and health care professionals. J Diabetes Sci Technol. 2010;4:1476–8. [PMC free article] [PubMed] [Google Scholar]
  17. Pfützner A, Bailey T, Campos C, Kahn D, Ambers E, Niemeyer M, et al. Accuracy and preference assessment of prefilled insulin pen versus vial and syringe with diabetes patients, caregivers, and healthcare professionals. Curr Med Res Opin. 2013;29:475–81. [PubMed] [Google Scholar]
  18. Xue L, Mikkelsen KH. Dose accuracy of a durable insulin pen with memory function, before and after simulated lifetime use and under stress conditions. Expert Opin Drug Deliv. 2013;10:301–6. [PubMed] [Google Scholar]
  19. Garg S, Bailey T, DeLuzio T, Pollom D. Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin. 2011;27:2323–33. [PubMed] [Google Scholar]
  20. Krzywon M, van der Burg T, Fuhr U, Schubert-Zsilavecz M, Abdel-Tawab M. Study on the dosing accuracy of commonly used disposable insulin pens. Diabetes Technol Ther. 2012;14:804–9. [PMC free article] [PubMed] [Google Scholar]
  21. Marcus A. Diabetes care — Insulin delivery in a changing world. Medscape J Med. 2008;20:10–120. [PMC free article] [PubMed] [Google Scholar]
  22. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430–2. [PubMed] [Google Scholar]
  23. Hirsch IB. Does size matter? Thoughts about insulin pen needles. Diabetes Technol Ther. 2012;14:1081. [PubMed] [Google Scholar]
  24. Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: Effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35:923–33.e4. [PubMed] [Google Scholar]
  25. Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BH. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011;13:737–41. [PMC free article] [PubMed] [Google Scholar]
  26. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988;81:435–41. [PMC free article] [PubMed] [Google Scholar]
  27. Kadish AH. A servomechanism for blood sugar control. Biomed Sci Instrum. 1963;1:171–6. [PubMed] [Google Scholar]
  28. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics. 2001;107:351–6. [PubMed] [Google Scholar]
  29. Skyler JS, Ponder S, Kruger DF, Matheson D, Parkin CG. Is there a place for insulin pump therapy in your practice? Clin Diabetes. 2007;25:50–6. [Google Scholar]
  30. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: The impact of baseline A1c. Diabetes Care. 2004;27:2590–6. [PubMed] [Google Scholar]
  31. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomised controlled trials. BMJ. 2002;324:705. [PMC free article] [PubMed] [Google Scholar]
  32. Müller-Godeffroy E, Treichel S, Wagner VM. German Working Group for Paediatric Pump Therapy. Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus — a large-scale multicentre pilot study. Diabet Med. 2009;26:493–501. [PubMed] [Google Scholar]
  33. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: A meta-analysis. Diabetes Care. 2003;26:1079–87. [PubMed] [Google Scholar]
  34. Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012;97:16–26. [PubMed] [Google Scholar]
  35. Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: A prospective 6-month study. Diabetes Care. 2011;34:574–9. [PMC free article] [PubMed] [Google Scholar]
  36. Garg SK. Role of continuous glucose monitoring in patients diabetes using multiple daily insulin injection. Infusystems Int. 2009;8:18–21. [Google Scholar]
  37. Cohen O, Körner A, Chlup R, Zoupas CS, Ragozin AK, Wudi K, et al. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: Prospective results from a community and academic practice patient registry. J Diabetes Sci Technol. 2009;3:804–11. [PMC free article] [PubMed] [Google Scholar]
  38. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20. [PubMed] [Google Scholar]
  39. Sovik O, Thordarson H. Dead-in-bed syndrome in young diabetic patients. Diabetes Care. 1999;22(Suppl 2):B40–2. [PubMed] [Google Scholar]
  40. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. 2012;35:1814–6. [PMC free article] [PubMed] [Google Scholar]
  41. Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, et al. The ASPIRE study: Design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J Diabetes Sci Technol. 2011;5:1466–71. [PMC free article] [PubMed] [Google Scholar]
  42. Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: The in-clinic ASPIRE study. Diabetes Technol Ther. 2012;14:205–9. [PubMed] [Google Scholar]
  43. Beck RW, Raghinaru D, Wadwa RP, Chase HP, Maahs DM, Buckingham BA, et al. Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care. 2014;37:1224–9. [PMC free article] [PubMed] [Google Scholar]
  44. Danne T, Kordonouri O, Holder M, Haberland H, Golembowski S, Remus K, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther. 2011;13:1129–34. [PubMed] [Google Scholar]
  45. Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32. [PubMed] [Google Scholar]
  46. Finn T. Medtronic Unveils FDA-Approved “Artificial Pancreas”-T1 Diabetes Patients Need to Take Note. Healthcare Matters Healthcare Matters. 2013. Oct 1, [Last accessed on 2013 Oct 27]. Available from: http://www.hcmatters.com/2013/10/medtronic-unveils-fda-approvedartificial-pancreas-t1-diabetes-patients-need-to-take-note/
  47. Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of diabetes: Past, present, and future. Diabetes Technol Ther. 2014;16:477–90. [PubMed] [Google Scholar]
  48. Soares S, Costa A, Sarmento B. Novel non-invasive methods of insulin delivery. Expert Opin Drug Deliv. 2012;9:1539–58. [PubMed] [Google Scholar]
  49. Gänsslen M. Über inhalation von insulin. Klin Wochenschr. 1925;4:71. [Google Scholar]
  50. Wigley FW, Londono JH, Wood SH, Shipp JC, Waldman RH. Insulin across respiratory mucosae by aerosol delivery. Diabetes. 1971;20:552–6. [PubMed] [Google Scholar]
  51. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J. 1987;23:293–7. [PubMed] [Google Scholar]
  52. Heinemann L. Alternative delivery routes: Inhaled insulin. Diabetes Nutr Metab. 2002;15:417–22. [PubMed] [Google Scholar]
  53. FDA Approved Drug Products. [Last accessed on 2013 Oct 27]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails .
  54. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43:781–801. [PubMed] [Google Scholar]
  55. Alabraba V, Farnsworth A, Leigh R, Dodson P, Gough SC, Smyth T. Exubera inhaled insulin in patients with type 1 and type 2 diabetes: The first 12 months. Diabetes Technol Ther. 2009;11:427–30. [PubMed] [Google Scholar]
  56. Flood T. Advances in insulin delivery systems and devices: Beyond the vial and syringe. Insulin. 2006;1:99–108. [Google Scholar]
  57. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. 2007;9(Suppl 1):S65–72. [PubMed] [Google Scholar]
  58. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother. 2010;44:1231–9. [PubMed] [Google Scholar]
  59. Thipphawong J, Otulana B, Clauson P, Okikawa J, Farr SJ. Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol Ther. 2002;4:499–504. [PubMed] [Google Scholar]
  60. Arbit E, Kidron M. Oral insulin: The rationale for this approach and current developments. J Diabetes Sci Technol. 2009;3:562–7. [PMC free article] [PubMed] [Google Scholar]
  61. Oral Delivery of Insulin: Novel Approaches. [Last accessed on 2013 Nov 10]. Available from: http://www.cdn.intechopen.com/pdfs/40267/InTech-Oral_delivery_of_insulin_novel_approaches.pdf .
  62. Sonia TA, Sharma CP. An overview of natural polymers for oral insulin delivery. Drug Discov Today. 2012;17:784–92. [PubMed] [Google Scholar]
  63. Ramesan RM, Sharma CP. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev Med Devices. 2009;6:665–76. [PubMed] [Google Scholar]
  64. Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2008;5:45–68. [PubMed] [Google Scholar]
  65. Chaturvedi K, Ganguly K, Nadagouda MN, Aminabhavi TM. Polymeric hydrogels for oral insulin delivery. J Control Release. 2013;165:129–38. [PubMed] [Google Scholar]
  66. Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: A review of formulation development and preclinical evaluation. J Diabetes Sci Technol. 2009;3:1451–9. [PMC free article] [PubMed] [Google Scholar]
  67. Heinemann L. New ways of insulin delivery. Int J Clin Pract Suppl. 2010;166:29–40. [PubMed] [Google Scholar]
  68. Sakloetsakun D, Dünnhaupt S, Barthelmes J, Perera G, Bernkop-Schnürch A. Combining two technologies: Multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. Int J Biol Macromol. 2013;61:363–72. [PubMed] [Google Scholar]
  69. Maroni A, Zema L, Del Curto MD, Foppoli A, Gazzaniga A. Oral colon delivery of insulin with the aid of functional adjuvants. Adv Drug Deliv Rev. 2012;64:540–56. [PubMed] [Google Scholar]
  70. Yaturu S. Insulin therapies: Current and future trends at dawn. World J Diabetes. 2013;4:1–7. [PMC free article] [PubMed] [Google Scholar]
  71. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A, et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N Engl J Med. 1985;312:1078–84. [PubMed] [Google Scholar]
  72. Frauman AG, Cooper ME, Parsons BJ, Jerums G, Louis WJ. Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care. 1987;10:573–8. [PubMed] [Google Scholar]
  73. Leary AC, Stote RM, Cussen K, O'Brien J, Leary WP, Buckley B. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: A preliminary study. Diabetes Technol Ther. 2006;8:81–8. [PubMed] [Google Scholar]
  74. Illum L. Nasal drug delivery — Recent developments and future prospects. J Control Release. 2012;161:254–63. [PubMed] [Google Scholar]
  75. Stote R, Marbury T, Shi L, Miller M, Strange P. Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol. 2010;4:603–9. [PMC free article] [PubMed] [Google Scholar]
  76. Benedict C, Frey WH, 2nd, Schiöth HB, Schultes B, Born J, Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol. 2011;46:112–5. [PubMed] [Google Scholar]
  77. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol. 2012;69:29–38. [PMC free article] [PubMed] [Google Scholar]
  78. Heinemann L, Jacques Y. Oral insulin and buccal insulin: A critical reappraisal. J Diabetes Sci Technol. 2009;3:568–84. [PMC free article] [PubMed] [Google Scholar]
  79. Kumria R, Goomber G. Emerging trends in insulin delivery: Buccal route. J Diabetol. 2011;2:1–9. [Google Scholar]
  80. Generex & Lilly dissolve Oralin Insulin Spray collaboration. [Last accessed on 2013 Nov 10]. Available from: http://www.islet.org/forum029/messages/26908.htm .
  81. First Oral Insulin Spray Launched in India. [Last accessed on 2013 Nov 10];Asia Pacific Biotech News. 2008 12:60. Available from: http://www.worldscientific.com/doi/abs/10.1142/S0219030308000918 . [Google Scholar]
  82. Generex Provides Update on Generex Oral-ly Conference Call. PR News wire. WORCESTER, Mass. and TORONTO. 2013. Sep 27, [Last accessed on 2013 Nov 10]. Available from: http://www.prnewswire.com/news-releases/generex-provides-update-on-generex-oral-lyn-conferencecall-225497092.html .
  83. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3:67–76. [PMC free article] [PubMed] [Google Scholar]
  84. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–8. [PMC free article] [PubMed] [Google Scholar]
  85. Kanikkannan N. Iontophoresis-based transdermal delivery systems. BioDrugs. 2002;16:339–47. [PubMed] [Google Scholar]
  86. Rao R, Nanda S. Sonophoresis: Recent advancements and future trends. J Pharm Pharmacol. 2009;61:689–705. [PubMed] [Google Scholar]
  87. Andrews S, Lee JW, Choi SO, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. Pharm Res. 2011;28:2110–8. [PMC free article] [PubMed] [Google Scholar]
  88. Charoo NA, Rahman Z, Repka MA, Murthy SN. Electroporation: An avenue for transdermal drug delivery. Curr Drug Deliv. 2010;7:125–36. [PubMed] [Google Scholar]
  89. Malakar J, Sen SO, Nayak AK, Sen KK. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J. 2012;20:355–63. [PMC free article] [PubMed] [Google Scholar]
  90. Freckmann G, Pleus S, Haug C, Bitton G, Nagar R. Increasing local blood flow by warming the application site: Beneficial effects on postprandial glycemic excursions. J Diabetes Sci Technol. 2012;6:780–5. [PMC free article] [PubMed] [Google Scholar]
  91. Freckmann G, Pleus S, Westhoff A, Krinelke LG, Buhr A, Jendrike N, et al. Clinical performance of a device that applies local heat to the insulin infusion site: A crossover study. J Diabetes Sci Technol. 2012;6:320–7. [PMC free article] [PubMed] [Google Scholar]
  92. Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: Experience with subcutaneous injection and continuous infusion. Endocr Pract. 2011;17:914–21. [PubMed] [Google Scholar]
  93. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: An emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64:11–29. [PubMed] [Google Scholar]
  94. Botz CK, Leibel BS, Zingg W, Gander RE, Albisser AM. Comparison of peripheral and portal routes of insulin infusion by a computer-controlled insulin infusion system (artificial endocrine pancreas) Diabetes. 1976;25:691–700. [PubMed] [Google Scholar]
  95. Van Dijk P. Intraperitoneal insulin. Diapedia the Living Textbook of Diabetes. 2013. [Last accessed on 2013 Nov 12]. Available from: http://www.diapedia.org/type-1-diabetes-mellitus/2104588419/intraperitoneal-insulin .
  96. Renard E. Insulin delivery route for the artificial pancreas: Subcutaneous, intraperitoneal, or intravenous? Pros and cons. J Diabetes Sci Technol. 2008;2:735–8. [PMC free article] [PubMed] [Google Scholar]
  97. Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Bélicar P, Guerci B, et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: The EVADIAC experience. Diabetes Metab. 2003;29:602–7. [PubMed] [Google Scholar]
  98. Kumareswaran K, Evans ML, Hovorka R. Closed-loop insulin delivery: Towards improved diabetes care. Discov Med. 2012;13:159–70. [PubMed] [Google Scholar]
  99. Morgan RV. Delivery of systemic regular insulin via the ocular route in cats. J Ocul Pharmacol Ther. 1995;11:565–73. [PubMed] [Google Scholar]
  100. Ritschel WA, Ritschel GB, Ritschel BE, Lücker PW. Rectal delivery system for insulin. Methods Find Exp Clin Pharmacol. 1988;10:645–56. [PubMed] [Google Scholar]
  101. Yamasaki Y, Shichiri M, Kawamori R, Kikuchi M, Yagi T, Ara S, et al. The effectiveness of rectal administration of insulin suppository on normal and diabetic subjects. Diabetes Care. 1981;4:454–8. [PubMed] [Google Scholar]
  102. Laqueur E, Grevenstuk A. Uber die wirkung intratrachealer zuführung von insulin. Klin Wochenschr. 1924;3:1273–4. [Google Scholar]

Photo
Pallavi Saxena
Corresponding author

Kalka Institute For Research and Advanced Studies, Partapur by pass Meerut.

Photo
Mohd Shuaib
Co-author

Kalka Institute For Research and Advanced Studies, Partapur by pass Meerut.

Photo
Abhinay Gupta
Co-author

Kalka Institute For Research and Advanced Studies, Partapur by pass Meerut.

Pallavi Saxena, Mohd Shuaib, Abhinay Gupta, Ancient methods and Novel methods of Insulin delivery, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 9, 288-303. https://doi.org/10.5281/zenodo.8344505

More related articles
Acebrophylline Is A Better Choice Of Drug Over The...
Sourav Pattanayak, Sagar Sheel, Vikash Kumar, ...
Nanotechnology Meets Targeted Therapy: Engineering...
Gaikwad Vaishnavi , Palghadmal Varsharani , Throat Suvarna , ...
Formulation And Evaluation Of Tranexamic Acid Sust...
Aswani Dukka, Bhagyasree Molii, ...
View more
Formulation And Evaluation Study Of Herbal Buccal Patch For Mouth Ulcer With Cur...
Daphne Sherine S, Ravichandran S., Abjel A., Gopi S., Sukesh Kumar B., ...
Drug-Device Combinations And Materiovigilance In The Cardiology Department Of A ...
Abhirami Jose, Jeeva Santhiya, eepika Kumar, Anjali M. A., Manjula Devi A. S, R. Vickram Vignesh, ...
Treating Wounds Using Nano Drugs Delivery Systems: Focusing On Metal Nanoparticl...
Swardhuni Pawar, Pratham Murkute, Prachiti Nayak, Smita Pol, Amit Mourya, Sonali Gopale, ...
View more
Download PDF
Related Articles
Cancer Vaccines Delivery Systems: Strategies For Efficient Targeting And Immuniz...
Parikshit Nagda, Krishna Hingad, Ghisulal Dewasi, Nirmal Sodha , Nihal Singh Rao, Bhaktraj Singh Cha...
Quantification of a Carcinogenic and Cytotoxic compound HMF 5 hydroxymethyl 2 fu...
Pranjali singh, C. Sreedhar, ...
Formulation And Evaluation of Herbal Body Wash Solution ...
Tanuja Kadam , Bahaisti Patel, Sakshi Labhade , Rutuja Shirode , Shubham Bodkhe , Roshni Sayyad, Ka...
Development And Characterization Of Liposphere Of Antidiabetic Drug Nateglinide ...
Kajal Bilgaiyan, Kaushelendra Mishra, Kajal Sharma, Parul Mehta, ...
Acebrophylline Is A Better Choice Of Drug Over Theophylline For Patients With As...
Sourav Pattanayak, Sagar Sheel, Vikash Kumar, ...
More related articles
Acebrophylline Is A Better Choice Of Drug Over Theophylline For Patients With As...
Sourav Pattanayak, Sagar Sheel, Vikash Kumar, ...
Nanotechnology Meets Targeted Therapy: Engineering Nanoparticles for Enhanced Dr...
Gaikwad Vaishnavi , Palghadmal Varsharani , Throat Suvarna , ...
Formulation And Evaluation Of Tranexamic Acid Sustained Release (Sr) Tablets...
Aswani Dukka, Bhagyasree Molii, ...
View more

Copyright © 2024 IJPS. All rights reserved